STOCK TITAN

Bio Rad Labs Inc - BIO STOCK NEWS

Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.

Bio-Rad Laboratories, Inc. (BIO) delivers essential innovations in clinical diagnostics and life science research through its global operations. This dedicated news hub provides investors and industry professionals with timely access to official announcements, financial updates, and scientific advancements.

Discover comprehensive collection of press releases covering quarterly earnings, regulatory milestones, product launches, and strategic partnerships. Our curated feed ensures transparent access to BIO's operational developments across its dual focus areas: laboratory-quality diagnostic systems and cutting-edge research tools.

Key updates include innovations in digital PCR technology, quality control solutions for clinical testing, and advancements supporting biopharmaceutical development. Bookmark this page for direct access to primary-source information affecting BIO's market position and research impact.

Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO) has announced it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after market close. The company, a global leader in life science research and clinical diagnostics products, will host a conference call at 2:30 PM Pacific Time (5:30 PM Eastern Time) to discuss the results.

Interested participants can join the call by dialing (800) 715-9871 within the U.S. or (646) 307-1963 internationally, using access code: 9562470. A live webcast will be available in the Investor Relations section of Bio-Rad's website, with the replay accessible for up to one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences earnings
-
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO) reported Q4 2024 financial results with total net sales of $667.5 million, down 2.0% from Q4 2023. The Life Science segment saw a 5.5% decline to $275.0 million, while Clinical Diagnostics segment increased 0.9% to $392.5 million.

For full-year 2024, revenue decreased 3.9% to $2,566.5 million. The company reported a net loss of $1,844.2 million ($65.36 per share), largely due to changes in fair market value of Sartorius AG investment. Non-GAAP net income was $291.1 million ($10.31 per share).

Bio-Rad announced plans to acquire Stilla Technologies, expecting to close by Q3 2025. The company projects 2025 non-GAAP currency-neutral revenue growth of 1.5-3.5% and operating margin of 13.0-13.5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
-
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO) has announced a binding offer to acquire Stilla Technologies, a developer of next-generation digital PCR solutions. The acquisition, expected to close by the end of Q3 2025, aims to complement Bio-Rad's existing digital PCR portfolio.

Stilla, operating in France and the U.S., develops the Nio® family of all-in-one digital PCR systems, which supports genetic testing across multiple applications including liquid biopsy, oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.

The integration would enhance Bio-Rad's capabilities in applied research and clinical diagnostics, particularly in areas requiring higher automation and throughput. Together with Bio-Rad's planned launch of the QX Continuum™ system, the combined platforms would serve a full range of digital PCR applications in genomics research and applied science.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) to discuss the results. Investors can join via phone by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) using access code 9562470. A live webcast will be available in the Investor Relations section of Bio-Rad's website, with the replay accessible for up to one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences earnings
-
Rhea-AI Summary

Geneoscopy has successfully closed a $105 million Series C funding round, led by Bio-Rad Laboratories (NYSE: BIO). The funding will support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.

The investment round included participation from notable investors including Petrichor, Labcorp, Morningside Ventures, and others. Geneoscopy's technology combines RNA isolation from stool samples with Bio-Rad's Droplet Digital™ PCR technology for effective cancer screening. Through a partnership with Labcorp, ColoSense will be made widely available to healthcare providers.

This funding follows FDA approval of ColoSense and aims to address the rising incidence of colorectal cancer, particularly among people under 50. The test offers a non-invasive alternative to traditional colonoscopies, potentially increasing screening accessibility for millions of eligible individuals who currently avoid testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its participation in J.P. Morgan's 43rd Annual Healthcare Conference. The company's leadership team, including CEO Norman Schwartz, COO Jon DiVincenzo, and CFO Roop K. Lakkaraju, will conduct one-on-one meetings with analysts and investors during the conference, which is scheduled to take place in San Francisco, CA from January 13-16, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
conferences
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B) has announced its participation in Citi's 2024 Global Healthcare Conference in Miami, FL, scheduled for December 3-5, 2024. The company's CEO Norman Schwartz and CFO Roop K. Lakkaraju will conduct one-on-one meetings with analysts and investors during the event. Bio-Rad, recognized as a global leader in life science research and clinical diagnostics products, aims to engage directly with the investment community through these meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences
-
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its participation in the UBS Global Healthcare Conference. CEO Norman Schwartz and CFO Roop K. Lakkaraju will engage in a fireside chat on Wednesday, November 13, 2024, at 1:15 PM Pacific Time. The event will be accessible via live webcast and replay through the Investor Relations section of Bio-Rad's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.35%
Tags
conferences
-
Rhea-AI Summary

Bio-Rad Laboratories reported Q3 2024 financial results with total net sales of $649.7 million, up 2.8% from Q3 2023. Clinical Diagnostics segment saw a 5.6% increase to $388.8 million, while Life Science segment decreased 1.0% to $260.9 million. The company's gross margin improved to 54.8% from 53.1%. Income from operations was $64.5 million, down from $90.9 million in Q3 2023. Net income significantly increased to $653.2 million ($23.34 per share), largely due to changes in fair market value of Sartorius AG investment. The company maintains its full-year 2024 outlook with expected non-GAAP revenue decline of 2.5-4.0% on a currency-neutral basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.35%
Tags
Rhea-AI Summary

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced it will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) on the same day to discuss the results.

Interested parties can participate in the call by dialing 800-579-2543 within the U.S. or 785-424-1789 outside the U.S., using the access code: BIORAD. Additionally, a live webcast of the conference call will be available in the "Investor Relations" section of Bio-Rad's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be accessible for up to one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences earnings
Bio Rad Labs Inc

NYSE:BIO

BIO Rankings

BIO Stock Data

6.67B
19.44M
15.56%
84.59%
3.08%
Medical Devices
Laboratory Analytical Instruments
Link
United States
HERCULES